

Global Journal of Health Science (GJHS)

**NEOPLASTIC DISORDERS OF VISUAL APPARATUS: ADVANCES AND
MANAGEMENT**

Dania, Afe Victor

Neoplastic Disorders of Visual Apparatus: Advances and Management



Dania, Afe Victor (OD; MPH; FNCO)

Corresponding Author's email address: info@iprjb.org.

Article History

Received 10th January 2023

Received in Revised Form 25th January 2023

Accepted 10th February 2023



Abstract

Purpose: Ocular neoplasms, both primary and metastatic, may present with visual disturbance or vision loss and often are asymptomatic. Clinical examination may demonstrate leukocoria, abnormal pupillary light reflex, or a mass lesion with or without retinal detachment or hemorrhage. Retinoblastoma in children and uveal melanoma and ocular metastases in adults are the most important ocular malignant neoplasms referred for imaging to aid with diagnosis and staging. Familiarity with their common imaging appearances, the common patterns of spread, and the diagnostic findings of greatest concern to the optometrist or ocular oncologist will enhance accuracy of imaging interpretation.

Methodology: Clinical examination and imaging using B-scan ultrasound, A-scan ultrasound, fluorescein angiography, computed tomography and magnetic resonance imaging have complementary roles in ocular tumor staging and treatment assessment.

Findings: Ocular neoplasm tumors are relatively rare but require unique diagnostic and treatment considerations given the functional importance of the eye and periocular structures and their unique metastatic behavior. In the following paper, a major malignant tumor of the ocular adnexa including the eyelid, conjunctiva and orbit will be reviewed. Frozen section control of the margins and, in selected cases, Mohs microsurgery have decreased the recurrence rate in malignant eyelid tumors. Intraoperative cryotherapy and postoperative topical mitomycin C have similarly contributed to better surgical outcomes in conjunctival malignant tumors including squamous cell carcinoma and malignant melanoma. Immunotherapy with CD20 antibodies is a developing treatment in Ocular neoplasm lymphomas.

Unique Contribution to Theory, Practice and Policy: Optometrists by the new advances in clinical optometry training/research, and specialists in oculoplasty/ocularistry form part of the team for a multidisciplinary approach in the clinical management of neoplastic disorders of visual apparatus.

Keywords: *Clinical Examination, Neoplastic disorder, Ocular Neoplasm*

@2023 by the Authors. This Article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>)

INTRODUCTION

Malignant Ocular neoplasm tumors comprise a diverse group of disorders. The outline of the major malignant tumors discussed in this paper are given in box 1. Ocular neoplasms, both primary and metastatic, may present with visual disturbance or vision loss and often are asymptomatic. Clinical optometric examination may demonstrate leukocoria, abnormal pupillary light reflex, or a mass lesion with or without retinal detachment or hemorrhage. Retinoblastoma in children and uveal melanoma and ocular metastases in adults are the most important ocular malignant neoplasms referred for imaging to aid with diagnosis and staging. Familiarity with their common imaging appearances, the common patterns of spread, and the diagnostic findings of greatest concern to the ocular oncologist will enhance accuracy of imaging interpretation. Clinical examination and imaging using B-scan ultrasound, A-scan ultrasound, fluorescein angiography, computed tomography and magnetic resonance imaging have complementary roles in ocular tumor staging and treatment assessment.

LITERATURE REVIEW

Malignant Eyelid Tumors & Predisposing Lesions:

Basal Cell Carcinoma

Clinical Features. Basal cell carcinoma (BCC) is the most common malignant eyelid tumor, accounting for 85% of all such tumors (Alizadeh et al., 1994). The tumor usually affects adults but may also occur in younger patients. Basal cell carcinoma arises in sun-exposed skin, implying that actinic damage is important in the pathogenesis. Basal cell carcinoma involves the lower eyelid in 55% of patients, the medial canthus in 30%, the upper eyelid in 10% and the lateral canthus in 5% (Lai et al., 2017). When BCC involves the eyelid margin, there is loss of lashes.

Clinically, there are two distinct types of BCC, nodular and morpheaform. The nodular type usually presents as an elevated mass with fairly well defined margins (Figure 1). Ulceration may develop. The morpheaform type, by contrast, has poorly defined borders and usually lacks ulceration. It is difficult to judge clinically where the margins of a morpheaform BCC are located.



Nodular basal cell carcinoma of the lower eyelid. Overall, 0.7% of basal cell tumors are a result of nevoid BCC syndrome (Gorlin-Goltz syndrome), an autosomal dominant disease (Q. Wang et al., 2008). Patients with this syndrome have multiple basal cell tumors, odontogenic keratocysts, bifid ribs, and palmar and plantar pits.

Histologic Features: Basal cell carcinoma is composed of cords of tumor cells with closely packed nuclei embedded in a dense fibrous tissue stroma. Deeper invasion into dermis may be seen with the morphea form type. There are several histopathologic variants of BCC, including the pigmented type, which contains melanin and thus can be confused with nevus or malignant melanoma. For treatment & prognosis, the best treatment option for BCC is complete surgical excision of the tumor with frozen section control of the surgical margins (Scott et al., 2003). Mohs micrographic surgery can also be used for control of tumor margins.

The eyelid defect created by tumor excision can be repaired using any of a variety of reconstructive methods. Modern oculoplastic surgical techniques can be used to repair a total full-thickness defect of the lower eyelid successfully, with good functional and cosmetic results. [9.....] Repair of upper eyelid defects may be more challenging but can usually be accomplished using two-stage eyelid-sharing procedures. In cases of locally advanced BCC with postseptal orbital invasion, orbital exenteration may be necessary (Shinomiya et al., 2013). External-beam radiation therapy may be appropriate for recurrent or extensive BCC that may not be amenable to complete surgical excision, or in patients who are poor candidates for surgery. Regional lymph node involvement or

systemic metastasis secondary to BCC is extremely rare. However, local recurrence may occur and is more frequent in incomplete excisions, in the setting of inner canthus and morpheaform-type tumors.

Preliminary studies using retinoids (etretinate and isotretinoin) in the management of BCC have yielded variable results (Thomas & Kaliyamurthy, 2013). A new class of immune-response modifier, represented by topical imiquimod cream was demonstrated to have some potential effect in the topical treatment of BCC, either alone or in combination with retinoids (Ebrahimiadib et al., 2016). Photodynamic therapy (PDT) is a new non-invasive procedure that produces tumor destruction. However, although PDT with α -aminolevulinic acid is a promising approach into therapy of dermal lesions, it is not yet an acceptable alternative in the treatment of BCC of the eyelids (Csepregi et al., 2018).

Keratoacanthoma

Clinical Features: Keratoacanthoma usually presents as a rapidly growing solitary nodule (Siagris et al., 2012). There is a distinctive central crater containing keratin debris. Keratoacanthoma usually occurs in immunocompromised patients and is possibly of viral origin. Regarding its pathology, Keratoacanthoma resembles low-grade squamous cell carcinoma (SCC), except for the presence of a central keratin-filled crater (Hardy et al., 2017). It shows acanthotic and dyskeratotic epithelium resembling SCC and is usually associated with an inflammatory cell response. For treatment, Keratoacanthoma is believed to represent a variant of SCC. Excisional biopsy is usually recommended. If there is uncertainty about the diagnosis, stationary lesions can be carefully observed (Jain et al., 2004). Keratoacanthoma may regress spontaneously over a period of 3 to 6 months.

Squamous Intraepithelial Neoplasia

Clinical Features: Squamous intraepithelial neoplasia (Bowen's disease) is considered to be squamous carcinoma in situ. It occurs most commonly in fair-skinned elderly individuals who have a history of chronic sun exposure. The majority of the patients are 60 years or older. Periocular squamous intraepithelial neoplasia occurs most frequently in the lower eyelid. It most often appears as a painless, elevated nodular or plaque-like lesion with chronic scaling and fissuring of the skin. Additional presenting features include a papillomatous lesion, a cutaneous horn and a large ulcerated lesion (J. Shields et al., 2004).

Pathology


There is marked squamous dysplasia without invasion beyond the basement membrane. Lipid or immunohistochemical stains may be necessary to differentiate between squamous intraepithelial neoplasia and intraepithelial spread of sebaceous gland carcinoma. The treatment strategy for squamous intraepithelial neoplasia consists of wide excision with clear margins, similar to that for SCC (Lowe et al., 2012).

Actinic Keratosis

Clinical Features: Actinic keratosis is a premalignant cutaneous lesion that predisposes to the development of SCC (Smoker et al., 2008). Actinic keratosis generally occurs in older fair-skinned individuals with a history of chronic sun exposure and usually presents as multiple slightly elevated erythematous lesions with patchy areas of ulceration. **Histologic Features,** Actinic keratosis is characterized by elastotic degeneration of the dermis, hyperkeratosis and elongation of the rete pegs of the skin. **For Treatment & Prognosis,** surgical resection of actinic keratosis may be the treatment of choice before transformation into SCC (Lowe et al., 2012). Topical chemotherapy with 5-fluorouracil (Effudex) may be appropriate in some clinical situations.

Squamous Cell Carcinoma

Clinical Features: Squamous cell carcinoma accounts for less than 5% of all malignant eyelid tumors (Sepahdari et al., 2010). In some series, SCC is the second most common malignant eyelid tumor after BCC; in other series, SCC is third most common, after sebaceous cell carcinoma (Ansari & Mafee, 2005; Y. Wang & Xiao, 2008). SCC can arise from a pre-existing actinic keratosis, Bowen's disease, keratoacanthoma, radiation dermatitis or de novo (Zhang et al., 2015). SCC may present as an elevated keratinized mass similar in appearance to BCC (Figure 2).



Squamous Cell Carcinoma of the Lower Eyelid Margin.

Histologic Features: Squamous cell carcinoma is comprised of proliferating malignant squamous cells with increased mitotic activity. In invasive SCC, tumor cells are seen below the epidermis. More differentiated tumors may produce keratin.

Treatment & Prognosis

The surgical principles as outlined for BCC also apply to SCC. Determination of tumor margins during surgical excision may be more difficult with SCC than with BCC, as SCC tends to have more ill-defined margins. SCC is associated with a risk of regional lymph node metastasis. For periocular SCC, the risk of regional lymph node metastasis may be as high as 20-30%, according to series from tertiary cancer centers (Ioannidis et al., 2018). Sentinel lymph node biopsy may be considered in high-risk patients, such as recurrent lesions or those with SCC greater than 2 cm in diameter or perineural invasion (Bacman et al., 2018). SCC is also associated with a risk of metastasis to distant organs, which increases with these high-risk features. Photodynamic therapy is emerging as a promising treatment for patients with multiple or large SCC in whom surgery is not appropriate. In such cases, PDT is associated with reasonable efficacy, good cosmesis and limited morbidity (Vemuganti et al., 2012). However, the precise role of PDT remains uncertain at this time.

Sebaceous Gland Carcinoma

Clinical Features: Sebaceous gland carcinoma (SGC) accounts for approximately 5% of all malignant eyelid tumors. SGC can originate from Meibomian glands, Zeis glands or the sebaceous glands of the caruncle. It may be multicentric in origin (J. Shields et al., 2004). Sebaceous gland carcinoma is more common in the upper eyelid but can also occur in the lower eyelid. It usually presents as a solitary yellow nodule resembling a chalazion. The pagetoid variety of SGC may resemble blepharoconjunctivitis in its clinical presentation. Like other malignant eyelid tumors, SGC may be associated with loss of lashes. SGC can invade and replace eyelid skin and conjunctival epithelium in a pagetoid fashion. The infiltrated epithelium is thickened and sometimes totally replaced by the tumor cells. Delayed or mistaken diagnosis is very common and thus locally advanced cases are not uncommon (Bouhout et al., 2017). If left untreated, the tumor has the ability to infiltrate postseptal orbital structures, including the lacrimal gland.

Patients with SGC of the eyelid should be screened for Muir-Torre syndrome, a rare autosomal dominant syndrome consisting of sebaceous gland tumors (hyperplasia, adenoma or carcinoma) and internal malignancies (colon cancer and other malignancies) (Bernardini et al., 2008; Croxatto & Font, 2018). A baseline colonoscopy, a gynecologic examination in women and other baseline imaging studies, to rule out other associated malignancies, are indicated at the time of initial diagnosis of SGC.

Histologic Features

Sebaceous gland carcinoma is composed of lobules or sheets of large, pleomorphic tumor cells with a foamy cytoplasm due to lipid vacuoles. The lipid can be demonstrated using special lipid stains such as Oil-red-O on fresh tissue that has not been formalin fixed. The central cells of SGC express human milk fat globulin (HMFG)-1 and epithelial membrane antigen (EMA), whereas the small peripheral basal and duct cells generally express cytokeratin. SGC also expresses Cam 5.2

and anti-BCA-255 (BRST-1), whereas BCC expresses neither EMA nor BRST-1 and SCC expresses EMA but not Cam 5.2 (Croxatto & Font, 2018). Therefore, a tumor that stains with EMA and Cam 5.2 is most likely to be SGC.

Treatment & Prognosis: The management of SGC consists of complete surgical excision with control of margins (Gengler & Guillou, 2006). There is controversy as to whether frozen sections, or Mohs surgery is preferable or if it is better to wait for permanent sections as it is difficult to diagnose SGC in frozen sections. Map biopsies of the eyelids and conjunctiva are obtained to rule out pagetoid involvement (Park & Araujo, 2009).

In the case of diffuse pagetoid intraepithelial neoplasia of the conjunctiva or eyelids and in the case of post-septal orbital invasion, orbital exenteration may be indicated as the best way to achieve local control. External-beam radiation therapy should be reserved for cases of recurrent or locally advanced disease, in which complete surgical excision cannot be accomplished and for patients who are poor candidates for extensive surgery. Topical chemotherapy with mitomycin C (MMC) has also been used successfully for the treatment of intraepithelial neoplasia (Raskin et al., 2015). Close follow-up is necessary because SGC is associated with a high risk of local recurrence, particularly if inadequately treated, and a risk of regional lymph node metastasis of approximately 10% according to most series. SGC can metastasize to distant organs such as the lung, liver, brain and skull. According to the Armed Forces Institute of Pathology (AFIP), the tumor-related mortality rate in patients with SGC is 15% (Politi et al., 2010). A more recent series by Shields and colleagues suggests a lower mortality rate, of less than 10% (Lloyd, 2001). Patients with the pagetoid variety have a worse prognosis.

Cutaneous Melanoma of the Eyelid & Periocular Region

Clinical Features: Cutaneous melanoma of the eyelid is relatively rare, accounting for fewer than 1% of all eyelid malignancies (Boukes & De Vries-Knoppert, 1985). Clinically, melanoma of the eyelid presents as a variably pigmented eyelid nodule and may demonstrate progressive growth. Periocular melanoma usually occurs in the malar region over an area of lentigo melanoma.

Histologic Features: Cutaneous melanoma is composed of neoplastic melanocytes (Rasmussen et al., 2011). All three histologic subtypes of melanoma (nodular, superficial spreading and lentigo maligna) can occur in the periocular region. Several studies have demonstrated that as with cutaneous melanomas in other locations, tumor thickness is an important predictor of regional lymph node metastasis and survival in patients with eyelid melanoma (Avery et al., 2011). Clark's microstaging does not apply to eyelid skin because the dermis is not stratified in papillary and reticular zones in this location, and there is no subcutaneous fat in the eyelid. The major prognostic parameter is the depth of invasion as measured from the top of the granular layer of the epidermis to the point of deepest invasion into the dermis.

Treatment & Prognosis: Management of eyelid and periocular melanoma is similar to management of other cutaneous melanomas. Wide surgical excision is the treatment of choice for local control. Control of surgical margins should be done but there is controversy about which technique is better. Frozen sections are controversial because they can induce some difficulties in the diagnosis. Mohs surgery (via serial mapped excision) may also be useful. In the head and neck

in general, and in the periocular region in particular, the WHO recommendation of at least 1 cm margins for melanomas less than or equal to 1 mm is not always possible if the goal is preservation of the globe and its function (Boukes & De Vries-Knoppert, 1985). Most surgeons aim for a 4-5 mm tumor-free margin on permanent formalin-fixed sections (Kornreich et al., 2001).

A patient with a newly diagnosed eyelid melanoma should undergo ultrasonography of the regional lymph nodes to rule out clinically positive lymph nodes. The role of sentinel lymph node biopsy for more accurate staging of the regional lymph nodes has evolved in the last decade (Ansari & Mafee, 2005). Eyelid melanomas are associated with a risk of distant organ metastasis, which can occur years after the initial diagnosis; thus, careful, long-term follow-up is prudent.

Merkel Cell Carcinoma

Clinical Features: Merkel cell carcinoma is a malignant tumor that arises from Merkel cells (mechanoreceptors for touch). The tumor generally occurs in older patients. Clinically, Merkel cell carcinoma usually presents as a reddish-blue lesion (Newman et al., 2011). It usually occurs in the upper eyelid but can also occur in the lower eyelid or in the periocular skin. The tumor has a tendency to metastasize to the regional lymph nodes in about 30-50% of the cases.

Treatment & Prognosis: Wide surgical excision followed by external-beam radiation therapy to the primary site is probably the best treatment although there is not enough information to assume that one particular approach is better than the other (Valvassori et al., 2019). Owing to the relatively high risk of regional lymph node metastasis (30-50%), consideration should be given to treatment of the regional lymph nodes (Avery et al., 2011). In selected cases, adjuvant chemotherapy may be recommended even in the absence of clinical evidence of metastasis at the time of initial diagnosis (Ahmed et al., 2008).

Metastatic Eyelid Tumors

Clinical Features: Metastatic eyelid tumors can originate from a variety of primary cancers including breast, lung and kidney, or from cutaneous melanoma (Gengler & Guillou, 2006). The eyelid mass may be the first sign of malignancy but is more commonly a new focus of metastasis in a patient with poorly controlled cancer at another site. Metastatic eyelid tumors are characterized by a rapidly growing eyelid nodule that may be mistaken for an inflammatory lesion.

Treatment & Prognosis: An incisional/excisional biopsy to establish the tumor diagnosis and to remove the lesion for palliative purposes may be appropriate (Ebrahimiadib et al., 2016). In patients who are poor candidates for surgery, external beam radiation therapy in addition to chemotherapy may also be used as a palliative measure.

Malignant Conjunctival Tumors & Predisposing Lesions:

Ocular Surface Squamous Neoplasia

Ocular surface squamous neoplasia (OSSN) is currently the preferred term for premalignant and malignant epithelial lesions of the cornea and conjunctiva and this review will approach these lesions in this form.

Clinical Features: Ocular surface squamous neoplasia has been associated with UV exposure, smoking, human papillomavirus types 16 and 18 and immunodeficiency, including immunodeficiency resulting from HIV infection (Tzioufas & Voulgarelis, 2007). A history of actinic skin lesions, such as solar keratosis and SCC is also strongly associated with the development of OSSN. OSSN usually presents as a fleshy limbal mass in the interpalpebral fissure (Figure 3). Rarely, the lesion involves the fornices. Clinically, the lesion may demonstrate leukoplakia (hyperkeratosis) on the surface and may appear papillomatous. The tumor can have prominent feeder vessels.



Figure 3: Conjunctival Squamous Cell Carcinoma of the Paralimbal Region

Histologic Features: Ocular surface squamous neoplasia consist of neoplastic cells arising in the conjunctival epithelium. Conjunctival intraepithelial neoplasia consists of partial displacement of epithelium by neoplastic cells. Invasive OSSN breaches the basement membrane and invades the conjunctival stroma. Specific variants of OSSN include mucoepidermoid carcinoma and spindle cell carcinoma, which are more invasive than other variants of OSSN (Parment, 1997).

Treatment & Prognosis: The treatment of OSSN varies with the size and location of the tumor, but the primary modality is complete surgical excision with cryotherapy applied to the excision margins (C. Shields & Shields, 1993). In cases with widespread involvement of the conjunctival

surface, it may be difficult to excise the tumor in one piece. Complete excision of the tumor may require a lamellar sclero-conjunctivectomy or a lamellar keratectomy at the limbus. After removal of the tumor, double freeze-thaw cryotherapy is applied to the conjunctival margins, and the conjunctiva is closed using absorbable sutures.

Topical chemotherapy with MMC (0.02-0.04%) or 5-fluorouracil (1%) can be used as postsurgical adjuvant therapy or to eradicate conjunctival intraepithelial neoplasia (Tzioufas & Voulgarelis, 2007). Some investigators employed interferon- α 2b via intralesional injection or via drops with complete resolution of the OSSN (Onyemocho et al., 2013). Irradiation in the form of episcleral plaque brachytherapy or proton-beam therapy has also been used in cases of recurrent or extensive disease (Korsten et al., 2017). Ocular surface squamous neoplasia rarely invades the globe or orbit. In such cases, enucleation or orbital exenteration may become necessary to fully eradicate the tumor. The risk of regional lymph node metastasis associated with OSSN is estimated to be less than 10%. Distant metastasis is rare. Owing to the high-risk of recurrence after treatment, long-term follow-up is necessary.

Conjunctival Primary Acquired Melanosis & Melanoma

Clinical Features: Primary acquired melanosis (PAM) presents as flat, diffuse or patchy areas of hyperpigmentation in the conjunctiva that moves over the sclera. In contrast to the conjunctival nevus, the lesion has no cysts in clinical examination. PAM can demonstrate a 'waxing and waning phenomenon' whereby the pigmentation in the lesion seems to vary over time. PAM can also be partially or totally amelanotic (sine pigmento). This may create difficulty in determining the clinical margins of the lesion.

Histopathologically, PAM is divided into two major groups: PAM without atypia and PAM with atypia. PAM with atypia is characterized by the presence of atypical melanocytes that have different sizes and shapes. Primary acquired melanosis of the conjunctiva has an average risk of 30% of evolution into a conjunctival melanoma. In PAM with atypia the risk is higher, at 45% (Raskin et al., 2015). In contrast to the much quoted AFIP series, recent data suggest that evolution of PAM into conjunctival melanoma is significantly lower at 8% at 5 years (Newman et al., 2011).

Conjunctival melanoma can originate from a pre-existing nevus, from PAM or de novo (Kornreich et al., 2001). The factors predisposing to the development of conjunctival melanoma are not known. Primary acquired melanosis with atypia is associated with a higher risk of malignant transformation into a conjunctival melanoma than are conjunctival nevi. Clinically, conjunctival melanoma presents as a variably pigmented mass (Figure 4). Some tumors are amelanotic. Recurrent melanomas in particular have a tendency to be amelanotic and may present as a subconjunctival amelanotic mass in the eyelid. Conjunctival melanomas can be associated with prominent feeder vessels and can involve the corneal limbus or the palpebral or forniceal conjunctiva. In locally advanced cases, conjunctival melanoma can invade the globe and the orbit.



Figure 4: Conjunctival Melanoma Involving the Bulbar Conjunctiva and the Corneal Limbus

Histologic Features: Histopathologically, PAM presents flat, brown intraepithelial lesions. It has been shown that with immunostaining for Ki-67 and proliferating cell nuclear antigen, PAM with atypia had significantly higher proliferation activity than PAM without atypia (Taneja *et al.*, 2013). Furthermore, there is a significantly higher expression of human melanoma black (HMB)-45 in PAM with atypia compared with PAM without atypia and conjunctival nevi (Vemuganti *et al.*, 2012).

Conjunctival melanoma is composed of malignant melanocytes with a spindle or epithelioid appearance. Tumor thickness is of great importance in predicting the risk of metastasis and survival and for selecting patients who may be candidates for sentinel lymph node biopsy.

Treatment & Prognosis: With PAM, there are certain features that necessitate treatment. Corneal involvement, palpebral involvement, more than 2 clock hours of involvement and elevation of the lesion are some of the features that necessitate treatment (Levitt *et al.*, 2015). Treatment usually involves superficial alcohol keratectomy, excision of the highly suspicious nodule, quadrant map biopsies and cryotherapy from underside of the conjunctiva. Topical chemotherapy using MMC 0.04% can be used as primary or supplemental treatment for extensive PAM (Bolaños-Jiménez *et al.*, 2015).

Treatment of conjunctival melanoma consists of complete surgical excision with cryotherapy applied to the excision margins (Croxatto & Font, 2018). Alcohol epitheliectomy and partial lamellar keratectomy may be necessary for lesions near the limbus involving the cornea. Adjuvant radiation therapy can be considered, depending on the location and extent of the tumor and may be delivered in the form of strontium applicators, radioactive plaques, or proton-beam radiation

therapy (Gengler & Guillou, 2006). Some investigators advocate treating primary acquired melanosis with topical chemotherapy as long as the invasive component is removed surgically. Topical MMC 0.04% chemotherapy may also be used for postsurgical treatment of invasive tumors after complete surgical resection, although which end points to use to measure efficacy in this setting are difficult to determine (Goldsmith et al., 2001). Owing to the high recurrence rate after treatment, extended follow-up is necessary.

Orbital exenteration may become necessary in patients who experience multiple local recurrences or with diffuse involvement of the conjunctiva and eyelid, or in patients not willing to come in for the necessary frequent follow-up visits. Orbital exenteration does not improve survival and is therefore performed only to achieve local control (Demirci et al., 2008).

According to several published series, conjunctival melanoma spreads to regional lymph nodes in 15-30% of patients (Levitt et al., 2015). Therefore, sentinel lymph node biopsy at the time of primary resection of the conjunctival melanoma may be prudent (Demirci et al., 2002). Our group has successfully performed sentinel lymph node biopsy in patients with palpebral or bulbar conjunctival melanomas and with this approach we have detected cases of histologically positive sentinel lymph nodes that would have gone undiagnosed otherwise (Ruchman & Flanagan, 2013). Systemic metastasis to brain, lung, liver, or other distant sites occurs in 10-30% of patients with conjunctival melanoma treated at most tertiary care centers (Constantopoulos et al., 2014). Tumor thickness greater than 2 mm and nonlimbal location are associated with increased risk of metastasis and death (Yousem et al., 2010).

Kaposi's Sarcoma

Clinical Features: Kaposi's sarcoma is caused by human herpesvirus 8 (Gengler & Guillou, 2006). It tends to occur in immunosuppressed individuals, especially those suffering from HIV infection (Mashoto et al., 2013). The lesion has a reddish appearance similar to that of a pyogenic granuloma, subconjunctival hemorrhage or foreign-body granuloma.

Treatment & Prognosis: In selected cases where the lesion is nodular, it can be excised. In cases with diffuse Kaposi's sarcoma, external-beam radiotherapy with a dose of 8 Gy in a single fraction is given (Demirci et al., 2002). Chemotherapy using interferon as well as active antiretroviral therapy have also been beneficial (Demirci et al., 2008).

Malignant Orbital Tumors in Adults (>18 Years of Age):

Lymphoid Tumors (Ocular neoplasm Lymphoma)

Clinical Features: Ocular neoplasm lymphoma (OAL) represents the malignant end of the spectrum of Ocular neoplasm lymphoproliferative disease; which has reactive lymphoid hyperplasia (RLH) and RLH with atypia as its benign and intermediate forms, respectively. The overall incidence of systemic lymphoma is increasing but no corresponding information exists for OAL. Ocular neoplasm lymphomas can affect the orbit, lacrimal gland, eyelids or the conjunctiva. It most often present as a nontender, firm, subcutaneous mass in the anterior orbit; as a conjunctival salmon-patch infiltrate; or as an eyelid infiltration (Ruchman & Flanagan, 2013). However, in 30-40% of patients, systemic involvement is seen 5-10 years after diagnosis of the orbital lymphoma.

Most OALs are of the non-Hodgkin's stage IE (extranodal) low-grade B-cell variety (Ruchman & Flanagan, 2013). More superficial tumors of T-cell lineage, such as mycosis fungoides, can also occur in the periocular skin and typically cause a secondary ectropion of the lower eyelid. Ocular neoplasm lymphomas may be associated with systemic lymphoma; thus, a full systemic work-up is required for staging of the lymphoma and to look for other foci of lymph node involvement. Lymphoid lesions typically mold to structures such as the globe and bony orbit. In the differential diagnosis of orbit and eyelid OALs, dacryoadenitis, inflammation, metastasis and benign and malignant tumors must be considered (Mearkle et al., 2016). Many lymphomas are thought to develop as a result of mistakes occurring during the normal lymphocyte response to infections or inflammation. There is increasing evidence of a role of chronic infection in OAL. Both *Chlamydia Psittaci* and *Helicobacter Pylori* have been identified to date in patients with OAL (Gengler & Guillou, 2006).

Histologic Features: The histopathologic spectrum for lymphoid tumors of the orbit ranges from benign reactive lymphoid hyperplasia to lymphoma. The histologic classification of lymphoma is beyond the scope of this review, but the Revised European-American Lymphoma (REAL) classification applies to tumors of the orbit. Most orbital lymphomas are of non-Hodgkin's B-cell type. OAL consists of five types of lymphoma, the most common of which is extranodal marginal zone (EMZL) or mucosa-associated lymphoid tissue (MALT) type followed by the follicular lymphoma. The other types including mantle cell lymphoma, diffuse large B-cell lymphoma and lymphoplasmacytic lymphoma are occasionally seen in the orbit. T-cell lymphoma is rare in the orbit and usually of the natural killer cell variety.

Treatment & Prognosis: As for other extranodal forms of lymphoma, the treatment of Ocular neoplasm lymphoma depends on the stage and histologic classification. For isolated Ocular neoplasm lymphoma (stage IE) of low grade, external-beam radiation therapy is considered the standard therapy (Parkin et al., 2005). For more widespread disease or for higher-grade lymphomas, systemic chemotherapy or a combination of chemotherapy and radiation therapy may be more appropriate (Croxatto & Font, 2018). Another alternative for stage IE low-grade lymphoma of the ocular adnexa, particularly low-grade B-cell follicular lymphoma or MALT lymphoma, may be monoclonal antibody therapy (Levitt et al., 2015). The most commonly used antibody is CD20, rituximab, which leads to the destruction of B cells using mechanisms of complement- and antibody-mediated destruction as well as induction of apoptosis. These antibodies are most commonly used in combination with other agents, so their solitary effect is hard to assess. They seem to reduce but not eliminate lymphoma. Monoclonal antibody therapy with rituximab (Rituxan) or ibritumomab tiuxetan (Zevalin) is also an intriguing option given that it targets CD20-positive lymphomas and is given systemically, thus potentially decreasing the likelihood of systemic recurrence during the follow-up period (Ruchman & Flanagan, 2013). Monoclonal antibody therapy may also be less toxic than systemic chemotherapy and may be associated with less ocular toxicity than radiation therapy.

Using a 3-week course of doxycycline, there was a therapeutic effect in half of patients, presumably to eradicate the infection that underlies lymphomagenesis. Another study has shown effect in a few patients using the typical anti-*H. Pylori* triple therapy (Demirci et al., 2002).

Controversy does exist as there are questions as to how antibiotic elimination of underlying infection could eradicate a genetic dysregulation. Fluorine 18 deoxyglucose (18FDG) PET proved to be useful in detecting systemic extranodal lymphomatous sites not detected in conventional imaging. Therefore, it may be used to evaluate systemic involvement in OAL patients (Levitt et al., 2015).

Malignant Epithelial Lacrimal Gland Tumors

Clinical Features: Malignant epithelial lacrimal gland tumors account for approximately 15-25% of all lacrimal gland tumors (Cytryn et al., 1997). Malignant tumors of the lacrimal gland include adenoid cystic carcinoma, pleomorphic adenocarcinoma and mucinous adenocarcinoma. Adenoid cystic carcinoma is the most common epithelial lacrimal gland malignancy but is still rare (Sepahdari et al., 2010). Although adenoid cystic carcinoma is more common in adults, it can also occur in children. Pain due to perineural invasion is a common complaint. Neuroimaging studies reveal a round to oval mass with irregular margins and bony destruction (Figure 5).



Figure 5: Oval Mass with Irregular Margins and Bony Destruction

CT scan of a locally advanced adenoid cystic carcinoma of the lacrimal gland. Note that the lacrimal gland mass fills the orbit to the orbital apex.

Histologic Features: The histologic features of malignant epithelial lacrimal gland tumors differ with the tumor type. Adenoid cystic carcinoma presents most commonly with a cribriform (swiss cheese) pattern; the basaloid (solid), sclerosing, tubular and comedocarcinoma patterns are also seen (Vemuganti et al., 2012). The basaloid variety has the worst prognosis (Cytryn et al., 1997). Perineural invasion is commonly seen with adenoid cystic carcinoma.

Treatment & Prognosis: Treatment consists of complete surgical resection, if possible. Radical surgery in the form of orbital exenteration with removal of orbital bony walls and postoperative radiation therapy (in the form of external-beam radiotherapy or, less commonly, plaque brachytherapy) is often indicated (Jung et al., 2007). Despite aggressive local therapy, a significant proportion of patients (>50% according to most series) develop metastatic disease; brain, bone and lung are the most common sites for distant metastasis (Jung et al., 2007). The mortality rate for adenoid cystic carcinoma of the lacrimal gland is greater than 50% at 5 years (Jung et al., 2007).

Metastatic Orbital Tumors

Clinical Features: Like metastatic uveal tumors, most orbital metastases reach the orbit by the hematogenous route. Most metastatic orbital tumors are carcinomas and, in rare cases, melanomas and sarcomas occur (Sepahdari et al., 2010). Breast, lung and prostate are the most common primary tumor sites; bronchial carcinoid, thyroid carcinoma and renal cell carcinoma are less common (Sepahdari et al., 2010). Clinically, a metastatic orbital tumor presents with rapid onset of proptosis and displacement of the globe. Pain, diplopia and blurred vision can also be the presenting signs and symptoms. Disease is usually unilateral, but occasionally it is bilateral. Fibrotic tumors of the breast and stomach may cause enophthalmos. Neuroimaging studies, including CT and MRI scanning, reveal a well-circumscribed lesion in the case of orbital metastasis from lung cancer, carcinoid, melanoma, thyroid carcinoma or renal cell carcinoma. Metastases from breast carcinoma often have a diffuse and ill-defined infiltrative appearance.

Treatment & Prognosis: Treatment of metastatic orbital tumors consists of an incisional biopsy if the diagnosis cannot be established on the basis of a previous history or imaging studies and if the location of the mass allows for a low-risk biopsy procedure. Systemic chemotherapy or local radiation therapy to the orbit can also be used for treatment of orbital metastases. In selected cases, hormonal therapy is also an option.

Secondary Tumors Extending to the Orbit from Adjacent Structures

Clinical Features: Secondary orbital tumors reach the orbit by direct extension from adjacent structures such as paranasal sinuses, nasal cavity, conjunctiva, eyelid or globe. Among the tumors that extend to the orbit are conjunctival SCC and conjunctival melanoma; eyelid tumors, including BCC, SCC, SGC and malignant melanoma of the eyelid; and intraocular tumors, including uveal melanoma, retinoblastoma and medulloepithelioma. Paranasal sinus carcinomas, nasopharyngeal carcinoma and angiofibroma, and sphenoid wing meningiomas can also invade the orbit.

Treatment & Prognosis: In many cases of orbital invasion from eyelid, conjunctival or intraocular tumors, orbital exenteration is indicated. The choice of an eyelid-sparing or eyelid-sacrificing technique depends on whether the eyelids are affected by tumor. On the other hand, in selected cases of orbital BCC, a globe-sparing orbital resection can be possible. Paranasal and nasopharyngeal carcinomas with orbital involvement require a multi-disciplinary approach involving specialists in head and neck surgery and neurosurgery. For extensive tumors not amenable to surgical resection, chemotherapy and external-beam radiation therapy can be used. In certain tumors such as sebaceous eyelid carcinoma or conjunctival malignant melanoma, additional lymph node resection should be considered when planning exenteration.

Malignant Orbital Tumors in Children (<18 Years of Age):

Rhabdomyosarcoma

Clinical Features: Rhabdomyosarcoma (RMS) is the most common primary malignant orbital tumor in children (Chirinos-Saldaña et al., 2013). The mean age at diagnosis is 8 years. RMS is occasionally congenital in onset. The tumor has a rather rapid onset, with proptosis and displacement of the globe. There may be eyelid edema and conjunctival chemosis resembling idiopathic orbital inflammation. Orbital imaging studies with contrast enhancement reveal a well-circumscribed and later diffuse mass. RMS originating from the nasopharynx can invade the orbit.

Histologic Features: Rhabdomyosarcoma is composed of poorly differentiated rhabdomyoblasts arranged in a loose myxomatous matrix. The characteristic tumor cell is the strap cell with cross striations. However, such cells are found in less than 60% of cases. The embryonal form is the most common form of RMS and the alveolar form is the most malignant. The pleomorphic form is least common and occurs in adults. The botryoid form is associated with a mucous membrane such as the conjunctiva. Alveolar RMS is less common, tends to arise in the inferior orbit, has a characteristic translocation (t [2;13]) and tends to have a poorer prognosis (Cytryn et al., 1997).

Immunohistochemistry aids in the diagnosis and determining the subtype of RMS. Numerous immunohistochemical markers including desmin, vimentin, muscle-specific actins, myoglobin, myogenin, myoD1, and caveolin-3 can identify the skeletal muscle-specific (SMA) expression in a RMS tumor. Antibodies against desmin show the greatest specificity and retain positive reaction in even poorly differentiated rhabdomyoblasts (Valvassori et al., 2019).

Treatment & Prognosis: A full metastatic evaluation should be included to rule out systemic involvement. The current Intergroup Rhabdomyosarcoma Study (IRS) treatment protocols, based on group, stage, histology and patient age, contribute to the risk and treatment stratification necessary to optimize outcome (Jung et al., 2007). A biopsy is necessary to establish the diagnosis. During the biopsy procedure, it is wise to remove as much tumor as possible without damaging vital orbital structures. Combined chemotherapy and irradiation are the mainstays of therapy for orbital RMS. Isolated orbital involvement carries the best prognosis of all primary RMS locations, with an overall survival rate of 96% (Sepahdari et al., 2010). Children who present between ages 1 and 10 years have a more favorable prognosis than infants and adults. Of the radiotherapy options, stereotactic radiotherapy with intensity-modulated radiotherapy (IMRT), proton beam radiation therapy and brachytherapy may produce similar results with fewer sequelae compared with the

standard EBRT (Cytryn et al., 1997). Standard EBRT leads to several complications including cataract, impaired vision, orbital hypoplasia and asymmetry, dry eye, and ptosis/enophthalmos in many patients.

Granulocytic Sarcoma (Chloroma)

Clinical Features: Soft tissue infiltration by myelogenous leukemia (a condition known as granulocytic sarcoma or chloroma) usually occurs in young children (Sepahdari et al., 2010). Systemic disease is usually present before the onset of orbital disease. However, in rare cases the orbital lesion is the first manifestation of myelogenous leukemia. Clinically, there is rapid onset with proptosis and displacement of the globe, alongside a palpable anterior orbital mass.

Conclusion

Early detection of neoplastic disease of the eye through judicious use of sentinel node biopsy and newer imaging modalities such as PET by the optometrist may make an overall difference in the survival of patients with aggressive tumors of the ocular adnexa. Optometrists who are specialists in oculastry/occuloplasty form part of the team. Expertise in eyelid and periocular reconstruction by the oculoplastic surgeon in the multidisciplinary management of eyelid, conjunctival and orbital cancers will allow for globe preservation and the use of adjuvant postoperative radiation therapy in lieu of radical surgery.

Early detection/diagnosis and professional referral by the Optometrists is key in the multidisciplinary management of neoplastic disorders of visual apparatus.

REFERENCES

- Ahmed, M., Niffenegger, J., Jakobiec, F., Ben-Arie-Weintrob, Y., Gion, N., & Androudi, S. (2008). Diagnosis of limited ophthalmic Wegener granulomatosis: distinctive pathologic features with ANCA test confirmation. *Int Ophthalmol*, 28(1), 35–46.
- Alizadeh, H., Pidherney, M., McCulley, J., & Niederkorn, J. (1994). Apoptosis as a mechanism of cytolysis of tumor cells by a pathogenic free-living amoeba. *Infect Immun*, 62(1), 298–303.
- Ansari, S., & Mafee, M. (2005). Orbital cavernous hemangioma: role of imaging. *Neuroimaging Clin N Am*, 15(1), 137–158.
- Avery, R., Fisher, M., & Liu, G. (2011). Optic pathway gliomas. *J Neuroophthalmol*, 31(3), 269–278.
- Bacman, S., Leiros, P. C., Sterin-Bora, L., Hubscher, O., Arana, R., & Borda, E. (2018). Autoantibodies against lacrimal gland M3 acetylcholine receptors in patients with primary Sjögren's syndrome. *Invest. Ophthalmol*, 39(37), 151–156.
- Bernardini, F., Devoto, M., & Croxatto, J. (2008). Epithelial tumors of the lacrimal gland: an update. *Curr Opin Ophthalmol*, 19(5), 409–413.
- Bolaños-Jiménez, R., Navas, A., López-Lizárraga, E., De Ribot, F., Peña, A., & Graue-Hernández, E. (2015). Ocular surface as barrier of innate immunity. *Open Ophthalmol J*, 9, 49–55.
- Bouhout, S., Robert, M., Deli, S., & Harissi-Dagher, M. (2017). Corneal Melt after Boston Keratoprosthesis: Clinical Presentation, Management, Outcomes and Risk Factor Analysis. *Ocul Immunol Inflamm.*, 12, 1–7.
- Boukes, R., & De Vries-Knoppert, W. (1985). Lacrimal gland enlargement as one of the ocular manifestations of Wegener's granulomatosis. *Doc Ophthalmol*, 59(1), 21–26.
- Chirinos-Saldaña, P., Bautista de Lucio, VM Hernandez-Camarena, J., Navas, A., Ramirez-Miranda, A., & Vizuet-Garcia, L. (2013). Clinical and microbiological profile of infectious keratitis in children. *BMC Ophthalmol*, 13(54).
- Constantopoulos, S., Drosos, A., Maddison, P., & Moutsopoulos, H. (2014). Xerotrachea and interstitial lung disease in primary Sjögren's syndrome. *Respiration*, 46(1), 310–314.
- Croxatto, J., & Font, R. (2018). Hemangiopericytoma of the orbit: a clinicopathologic study of 30 cases. *Hum Pathol*, 13(3), 210–218.
- Csepregi, A., Szdoray, P., & Zeher, M. (2018). Do autoantibodies predict autoimmune liver disease in primary Sjögren's syndrome? Data of 180 patients upon a 5-year follow-up. *Scand. J. Immunol*, 56, 623–629.
- Cytryn, A., Putterman, A., Schneck, G., Beckman, E., & Valvassori, G. (1997). Predictability of magnetic resonance imaging in differentiation of orbital lymphoma from orbital inflammatory syndrome. *Ophthal Plast Reconstr Surg*, 13(2), 129–134.

- Demirci, H., Shields, C., Karatza, E., & Shields, J. (2008). Orbital lymphoproliferative tumors: analysis of clinical features and systemic involvement in 160 cases. *Ophthalmology*, *115*(9), 1626–1631.
- Demirci, H., Shields, C., Shields, J., Honavar, S., Mercado, G., & Tovilla, J. (2002). Orbital tumors in the older adult population. *Ophthalmology*, *56*(7), 109.
- Ebrahimiadib, N., Modjtahedi, B., Roohipoor, R., Anesi, S., & Foster, C. (2016). Successful Treatment Strategies in Granulomatosis With Polyangiitis-Associated Peripheral Ulcerative Keratitis. *Cornea*, *35*(11), 1459–1465.
- Gengler, C., & Guillou, L. (2006). Solitary fibrous tumour and haemangiopericytoma: evolution of a concept. *Histopathology*, *46*(1), 63–74.
- Goldsmith, J., van de Rijn, M., & Syed, N. (2001). Orbital hemangiopericytoma and solitary fibrous tumor: a morphologic continuum. *Int J Surg Pathol*, *9*(4), 295–302.
- Hardy, S., Hashemi, K., Catanese, M., Candil, M., Zufferey, P., & Gabison, E. (2017). Necrotising Scleritis and Peripheral Ulcerative Keratitis Associated with Rheumatoid Arthritis Treated with Rituximab. *Klin Monbl Augenheilkd*, *234*(4), 567–570.
- Ioannidis, J., Vassiliou, V., & Moutsopoulos, H. (2018). Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome. *Arthritis Rheum*, *46*(18), 741–747.
- Jain, A., Sukhija, J., Saini, J., Chawla, Y., & Dhiman, R. (2004). Hepatitis C virus-associated keratitis. *Eye (Lond)*, *18*(2), 131–134.
- Jung, W., Ahn, K., & Park, M. (2007). The radiological spectrum of orbital pathologies that involve the lacrimal gland and the lacrimal fossa. *Korean J Radiol*, *8*(4), 336–342.
- Kornreich, L., Blaser, S., & Chwarz, M. (2001). Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatosis. *AJNR Am J Neuroradiol*, *22*(10), 1963–1969.
- Korsten, P., Bahlmann, D., & Patschan, S. (2017). Rapid healing of peripheral ulcerative keratitis in rheumatoid arthritis with prednisone, methotrexate and adalimumab combination therapy. *Rheumatology (Oxford)*, *14*.
- Lai, T., Far, N., Young, A., & Jhanji, V. (2017). Rapid corneal thinning and perforated ulcerative keratitis in a patient with relapsing polychondritis. *Eye Vis (Lond)*, *4*(8).
- Levitt, A., McManus, K., McClellan, A., Davis, J., Goldhardt, R., & Galor, A. (2015). Ocular Inflammation in the Setting of Concomitant Systemic Autoimmune Conditions in an Older Male Population. *Cornea*, *34*(7), 762–767.
- Lloyd, A. J. (2001). The extent of patients’ understanding of the risk of treatments. *Quality and Safety in Health Care*, *10*, 14–18.
- Lowe, L., Marchant, T., Rivard, D., & Scherbel, A. (2012). Vascular malformations: classification and terminology the radiologist needs to know. *Semin Roentgenol*, *47*(2), 106–117.

- Mashoto, K. O., Mubyazi, G. M., Mohamed, H., & Malebo, H. M. (2013). Self- reported occupational exposure to HIV and factors influencing its management practice: a study of healthcare workers in Tumbi and Dodoma Hospitals, Tanzania. *BMC Health Services Research*, 13(1), 276.
- Mearkle, R., Houghton, R., Bwonya, D., & Lindfield, R. (2016). Barriers to hand hygiene in Ophthalmic outpatients in Uganda: Mixed methods approach. *Journal of Ophthalmic Inflammation and Infection*, 6(11).
- Newman, C. J., De Vries, D. H., Kanakuze, J. D. A., & Ngendahimana, G. (2011). Workplace violence and gender discrimination in Rwanda's health workforce: Increasing safety and gender equality. *Human Resources for Health*, 9(1), 19.
- Onyemochu, A., Anekoson, J. I., & Pius, E. O. (2013). Knowledge and practice of injection safety among workers of Nigerian Prison Service health Facilities in Kaduna state. *Science and Education Publishing*, 7(5).
- Park, M., & Araujo, D. (2009). New insights into the hemangiopericytoma/solitary fibrous tumor spectrum of tumors. *Curr Opin Oncol*, 21(4), 327– 331.
- Parkin, B., Chew, J., White, V., Garcia-Briones, G., Chhanabhai, M., & Rootman, J. (2005). Lymphocytic infiltration and enlargement of the lacrimal glands: a new subtype of primary Sjögren's syndrome? *Ophthalmology*, 112(11), 2040–2047.
- Parment, P. (1997). The role of *Serratia marcescens* in soft contact lens associated ocular infections. A review. *Acta Ophthalmol Scand*, 75, 67–71.
- Politi, L., Forghani, R., & Godi, C. (2010). Ocular adnexal lymphoma: diffusion-weighted MR imaging for differential diagnosis and therapeutic monitoring. *Radiology*, 256(2), 565–574.
- Raskin, E., McCormick, S., Maher, E., Della, R., & Rocca, P. (2015). Granulomatous idiopathic orbital inflammation. *Ophthal Plast Reconstr Surg*, 11(2), 131–135.
- Rasmussen, P., Ralfkiaer, E., Prause, J., Sjö, L., Siersma, V., & Heegaard, S. (2011). Malignant lymphoma of the lacrimal gland: a nation-based study. *Arch Ophthalmol*, 129(10), 1275–1280.
- Ruchman, M., & Flanagan, J. (2013). Cavernous hemangiomas of the orbit. *Ophthalmology*, 22(8), 67–69.
- Scott, J., Maddison, P., Taylor, P., Esscher, E., Scott, O., & Skinner, R. (2003). Connective-tissue disease, antibodies to ribonucleoprotein, and congenital heart block. *N. Engl. J. Med*, 309(65), 209–212.
- Sepahdari, A., Aakalu, V., Setabutr, P., Shiehmorteza, M., Naheedy, J., & Mafee, M. (2010). Indeterminate orbital masses: restricted diffusion at MR imaging with echo-planar diffusion-weighted imaging predicts malignancy. *Radiology*, 256(2), 554–564.
- Shields, C., & Shields, J. (1993). Lacrimal gland tumors. *Int Ophthalmol Clin*, 33(3), 181–188.

- Shields, J., Shields, C., & Scartozzi, R. (2004). 1264 patients with orbital tumors and simulating lesions: the 2002 Montgomery Lecture, part 1. *Ophthalmology*, *111*(5), 997–1008.
- Shinomiya, K., Ueta, M., Sotozono, C., Inatomi, T., Yokoi, N., & Koizumi, N. (2013). Immunohistochemical analysis of inflammatory limbal conjunctiva adjacent to Mooren's ulcer. *Br J Ophthalmol*, *97*(3), 362–366.
- Siagris, D., Pharmakakis, N., & Christofidou, M. (2012). Keratoconjunctivitis sicca and chronic HCV infection. *Infection*, *30*(4), 229–233.
- Smoker, W., Gentry, L., Yee, N., Reede, D., & Nerad, J. (2008). Vascular lesions of the orbit: more than meets the eye. *RadioGraphics*, *28*(1), 185–204.
- Taneja, M., Ashar, J., Mathur, A., Nalamada, S., & Garg, P. (2013). Microbial keratitis following vegetative matter injury. *Int Ophthalmol*, *33*(1), 17–23.
- Thomas, P., & Kaliamurthy, J. (2013). Mycotic keratitis: Epidemiology, diagnosis and management. *Clin Microbiol Infect*, *19*(2), 10–20.
- Tzioufas, A., & Voulgarelis, M. (2007). Update on Sjögren's syndrome autoimmune epithelitis: from classification to increased neoplasias. *Best Pract Res Clin Rheumatol*, *21*(6), 989–1010.
- Valvassori, G., Sabnis, S., Mafee, R., Brown, M., & Putterman, A. (2019). Imaging of orbital lymphoproliferative disorders. *Radiol Clin North Am*, *37*(1), 135–150.
- Vemuganti, G., Garg, P., Gopinathan, U., Naduvilath, T., John, R., & Buddi, R. (2012). Evaluation of agent and host factors in progression of mycotic keratitis: A histologic and microbiologic study of 167 corneal buttons. *Ophthalmology*, *109*(15), 38–46.
- Wang, Q., Yuan, J., Zhou, S., & Chen, J. (2008). Chronic hepatitis C virus infection is not associated with Mooren's ulcer. *Eye (Lond)*, *22*(5), 697–700.
- Wang, Y., & Xiao, L. (2008). Orbital schwannomas: findings from magnetic resonance imaging in 62 cases. *Eye (Lond)*, *22*(8), 1034–1039.
- Yousem, D., Zimmerman, R., & Grossman, R. (2010). *Neuroradiology. Philadelphia*, *23*(12), 56.
- Zhang, N., Shi, C., & Yao, Q. (2015). Prevalence of primary Sjögren's syndrome in China. *J. Rheumatol*, *22*(24), 659–661.